Authors: Mendel, DB Laird, AD Smolich, BD Blake, RA Liang, CX Hannah, AL Shaheen, RM Ellis, LM Weitman, S Shawver, LK Cherrington, JM

Citation: Db. Mendel et al., Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent, ANTI-CAN DR, 15(1), 2000, pp. 29-41

Authors: Eckhardt, SG Rizzo, J Sweeney, KR Cropp, G Baker, SD Kraynak, MA Kuhn, JG Villalona-Calero, MA Hammond, L Weiss, G Thurman, A Smith, L Drengler, R Eckardt, JR Moczygemba, J Hannah, AL Von Hoff, DD Rowinsky, EK

Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104

Authors: Hebert, N Hannah, AL Sutton, SC

Citation: N. Hebert et al., Synthesis of oxadiazoles on solid support, TETRAHEDR L, 40(49), 1999, pp. 8547-8550